JP2020520368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520368A5 JP2020520368A5 JP2019563558A JP2019563558A JP2020520368A5 JP 2020520368 A5 JP2020520368 A5 JP 2020520368A5 JP 2019563558 A JP2019563558 A JP 2019563558A JP 2019563558 A JP2019563558 A JP 2019563558A JP 2020520368 A5 JP2020520368 A5 JP 2020520368A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- particles
- cancer
- poly
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022157413A JP2022188159A (ja) | 2017-05-17 | 2022-09-30 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
| JP2024131720A JP2024160312A (ja) | 2017-05-17 | 2024-08-08 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17171617 | 2017-05-17 | ||
| EP17171617.8 | 2017-05-17 | ||
| EP17382301.4 | 2017-05-26 | ||
| EP17382301 | 2017-05-26 | ||
| EP17200469.9 | 2017-11-07 | ||
| EP17200469 | 2017-11-07 | ||
| PCT/EP2017/079688 WO2018210439A1 (en) | 2017-05-17 | 2017-11-17 | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022157413A Division JP2022188159A (ja) | 2017-05-17 | 2022-09-30 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520368A JP2020520368A (ja) | 2020-07-09 |
| JP2020520368A5 true JP2020520368A5 (https=) | 2021-01-07 |
Family
ID=64273459
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563558A Pending JP2020520368A (ja) | 2017-05-17 | 2017-11-17 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
| JP2022157413A Pending JP2022188159A (ja) | 2017-05-17 | 2022-09-30 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
| JP2024131720A Pending JP2024160312A (ja) | 2017-05-17 | 2024-08-08 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022157413A Pending JP2022188159A (ja) | 2017-05-17 | 2022-09-30 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
| JP2024131720A Pending JP2024160312A (ja) | 2017-05-17 | 2024-08-08 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10849921B2 (https=) |
| EP (2) | EP4122449A1 (https=) |
| JP (3) | JP2020520368A (https=) |
| CN (2) | CN115998757A (https=) |
| AU (2) | AU2017414660A1 (https=) |
| CA (1) | CA3063805C (https=) |
| DK (1) | DK3448363T3 (https=) |
| ES (1) | ES2924138T3 (https=) |
| PL (1) | PL3448363T3 (https=) |
| WO (1) | WO2018210439A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE047172T2 (hu) * | 2015-11-17 | 2020-04-28 | Bioncotech Therapeutics S L | Újfajta gyógyszerészeti készítmény, mely egy kétszálú poli-ribonukleotid és egy polialkilén-imin egy komplexét tartalmazó részecskéket tartalmaz |
| ES2924138T3 (es) * | 2017-05-17 | 2022-10-04 | Highlight Therapeutics S L | Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina |
| US20210386780A1 (en) * | 2018-10-01 | 2021-12-16 | The Regents Of The University Of California | Methods for treating cancer with double stranded rna sensor activators and adoptive cell therapy |
| US20210346420A1 (en) * | 2018-10-10 | 2021-11-11 | The Regents Of The University Of California | Combination immunotherapies |
| EP4603098A3 (en) | 2018-11-01 | 2025-09-03 | Alpha Tau Medical Ltd. | Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen |
| US20210396737A1 (en) * | 2018-11-21 | 2021-12-23 | Highlight Therapeutics, S.L. | Nanoplexed poly(i:c) formulations and uses thereof |
| PY2265694A (es) * | 2021-07-30 | 2023-03-08 | Salazar Andres | Actividad biologica multidimensional optimizada de poli-iclc con tamaño y formulacion de componentes controlados |
| CN114525253B (zh) * | 2022-03-09 | 2024-03-15 | 南开大学 | 一种脂多糖诱导的外泌体及其应用 |
| US20240091348A1 (en) | 2022-09-20 | 2024-03-21 | Highlight Therapeutics, S.L. | Novel compositions based on polyinosinic-polycytidylic acid |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60021354T2 (de) * | 1999-02-15 | 2006-04-27 | Nippon Shinyaku Co., Ltd. | Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung |
| EP1778186B1 (en) | 2002-07-03 | 2011-11-30 | Oncovir, Inc. | Method for preparation of poly-iclc and uses thereof |
| US7927792B2 (en) | 2002-11-18 | 2011-04-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Targeted double stranded RNA mediated cell killing |
| US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
| JP4861036B2 (ja) | 2006-03-31 | 2012-01-25 | リンテック株式会社 | 剥離シートおよびその製造方法 |
| WO2008057696A2 (en) | 2006-10-10 | 2008-05-15 | Juvaris Biotherapeutics, Inc. | Compositions of pattern recognition receptor-ligand: lipid complexes and methods of use thereof |
| KR100958293B1 (ko) | 2008-03-27 | 2010-05-19 | 단국대학교 산학협력단 | 테오필린에 의해 표적 특이적 ｒｎａ 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 ｉ 리보자임 |
| WO2009130301A1 (en) * | 2008-04-25 | 2009-10-29 | Institut Gustave Roussy | Improved treatment of cancer using tlr3 agonists in combination with another therapeutic agent |
| WO2010073247A2 (en) * | 2008-12-22 | 2010-07-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Egfr-homing double-stranded rna vector for systemic cancer treatment |
| ES2368963B1 (es) * | 2009-07-04 | 2012-10-10 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado. |
| CN102988303A (zh) | 2011-09-15 | 2013-03-27 | 天津泽世德生物医药有限公司 | 一种多聚肌苷酸多聚胞苷酸冻干粉针的制备方法 |
| WO2013040552A2 (en) | 2011-09-16 | 2013-03-21 | Georgia Health Sciences University | Methods of promoting immune tolerance |
| WO2013063019A1 (en) | 2011-10-28 | 2013-05-02 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells |
| WO2013087083A1 (en) | 2011-12-15 | 2013-06-20 | Biontech Ag | Particles comprising single stranded rna and double stranded rna for immunomodulation |
| NZ630040A (en) | 2012-05-03 | 2016-10-28 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| US20140335154A1 (en) | 2013-03-12 | 2014-11-13 | Multicell Immunotherapeutics, Inc. | Methods and formulations to achieve tumor targeted double stranded rna mediated cell death |
| KR20160072140A (ko) | 2013-11-06 | 2016-06-22 | 얀센 사이언시즈 아일랜드 유씨 | 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형 |
| CN103599071B (zh) | 2013-11-08 | 2016-01-27 | 杭州美亚药业股份有限公司 | 一种双链聚肌胞干粉的制备方法 |
| KR102589295B1 (ko) | 2014-05-14 | 2023-10-13 | 타르그이뮨 테라퓨틱스 아게 | 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터 |
| EP3283059B1 (en) | 2015-04-13 | 2024-01-03 | CureVac Manufacturing GmbH | Method for producing rna compositions |
| MX2017014060A (es) * | 2015-05-05 | 2018-07-06 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Composiciones de acido nucleico-polimero cationico y metodos de fabricacion y uso de las mismas. |
| HUE047172T2 (hu) * | 2015-11-17 | 2020-04-28 | Bioncotech Therapeutics S L | Újfajta gyógyszerészeti készítmény, mely egy kétszálú poli-ribonukleotid és egy polialkilén-imin egy komplexét tartalmazó részecskéket tartalmaz |
| MX2019001920A (es) | 2016-08-19 | 2019-07-01 | Curevac Ag | Arn la terapia contra el cancer. |
| ES2924138T3 (es) * | 2017-05-17 | 2022-10-04 | Highlight Therapeutics S L | Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina |
-
2017
- 2017-11-17 ES ES17804148T patent/ES2924138T3/es active Active
- 2017-11-17 EP EP22172379.4A patent/EP4122449A1/en active Pending
- 2017-11-17 PL PL17804148.9T patent/PL3448363T3/pl unknown
- 2017-11-17 CN CN202310100333.0A patent/CN115998757A/zh active Pending
- 2017-11-17 CA CA3063805A patent/CA3063805C/en active Active
- 2017-11-17 EP EP17804148.9A patent/EP3448363B1/en active Active
- 2017-11-17 AU AU2017414660A patent/AU2017414660A1/en not_active Abandoned
- 2017-11-17 US US16/614,439 patent/US10849921B2/en active Active
- 2017-11-17 JP JP2019563558A patent/JP2020520368A/ja active Pending
- 2017-11-17 DK DK17804148.9T patent/DK3448363T3/da active
- 2017-11-17 CN CN201780092798.9A patent/CN110831581A/zh active Pending
- 2017-11-17 WO PCT/EP2017/079688 patent/WO2018210439A1/en not_active Ceased
-
2019
- 2019-12-23 US US16/724,519 patent/US10869881B2/en active Active
-
2020
- 2020-10-30 US US17/084,995 patent/US11883424B2/en active Active
- 2020-11-11 US US17/095,059 patent/US11896606B2/en active Active
-
2022
- 2022-09-30 JP JP2022157413A patent/JP2022188159A/ja active Pending
- 2022-11-16 US US17/988,625 patent/US12383575B2/en active Active
-
2024
- 2024-07-10 AU AU2024204758A patent/AU2024204758A1/en active Pending
- 2024-08-08 JP JP2024131720A patent/JP2024160312A/ja active Pending
-
2025
- 2025-07-07 US US19/261,229 patent/US20250332191A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520368A5 (https=) | ||
| Liu et al. | Tumor microenvironment‐responsive nanoparticles amplifying STING signaling pathway for cancer immunotherapy | |
| Han et al. | Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer | |
| Li et al. | Nanotechnology: breaking the current treatment limits of lung cancer | |
| Shen et al. | Alendronate triggered dual‐cascade targeting prodrug nanoparticles for enhanced tumor penetration and STING activation of osteosarcoma | |
| Guorgui et al. | Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice | |
| Zhou et al. | Nanoparticle‐mediated STING agonist delivery for enhanced cancer immunotherapy | |
| Norouzi et al. | Injectable hydrogel-based drug delivery systems for local cancer therapy | |
| Bauleth‐Ramos et al. | Acetalated dextran nanoparticles loaded into an injectable alginate cryogel for combined chemotherapy and cancer vaccination | |
| Zhang et al. | Metal coordination‐driven assembly of stimulator of interferon genes‐activating nanoparticles for tumor chemo‐immunotherapy | |
| Barzegar Behrooz et al. | Smart bomb AS 1411 aptamer‐functionalized/PAMAM dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer | |
| Kang et al. | Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier | |
| Yu et al. | Synergy of immunostimulatory genetherapy with immune checkpoint blockade motivates immune response to eliminate cancer | |
| Chen et al. | Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy | |
| Chen et al. | iRGD tumor-penetrating peptide-modified nano-delivery system based on a marine sulfated polysaccharide for enhanced anti-tumor efficiency against breast cancer | |
| Wang et al. | Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: a comparative study of molecular inhibitors and siRNA therapeutics | |
| Wu et al. | Promote intratumoral drug release and penetration to counteract docetaxel‐induced metastasis by photosensitizer‐modified red blood cell membrane‐coated nanoparticle | |
| US10632081B2 (en) | Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis | |
| Mollica et al. | Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer | |
| Wang et al. | Polysaccharide nanodonuts for photochemotherapy‐amplified immunogenic cell death to potentiate systemic antitumor immunity against hepatocellular carcinoma | |
| Li et al. | EGF‐functionalized lipid–polymer hybrid nanoparticles of 5‐fluorouracil and sulforaphane with enhanced bioavailability and anticancer activity against colon carcinoma | |
| Jiang et al. | Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity | |
| Li et al. | Co-delivery of Interleukin-12 and doxorubicin loaded Nano-delivery system for enhanced immunotherapy with polarization toward M1-type Macrophages | |
| Kazemi et al. | PNA-ATP aptamer-capped doxorubicin-loaded silica nanoparticles for targeted cancer therapy | |
| Jia et al. | Radioiodine‐131‐Labeled theranostic nanoparticles for transarterial radioembolization and chemoembolization combination therapy of VX2 liver tumor |